key: cord-0685204-rzv4hk32
authors: Wynberg, Elke; van Willigen, Hugo D G; Dijkstra, Maartje; Boyd, Anders; Kootstra, Neeltje A; van den Aardweg, Joost G; van Gils, Marit J; Matser, Amy; de Wit, Marije R; Leenstra, Tjalling; de Bree, Godelieve; de Jong, Menno D; Prins, Maria
title: Evolution of COVID-19 symptoms during the first 12 months after illness onset
date: 2021-09-02
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab759
sha: 4f23e2e59ab330efef9d9f387b9def8f25df2cde
doc_id: 685204
cord_uid: rzv4hk32

BACKGROUND: Few robust longitudinal data on long-term COVID-19 symptoms are available. We evaluated symptom onset, severity and recovery across the full spectrum of disease severity, up to one year after illness onset. METHODS: The RECoVERED Study is a prospective cohort study based in Amsterdam, the Netherlands. Participants aged≥18 years were enrolled following SARS-CoV-2 diagnosis via the local Public Health Service and from hospitals. Standardised symptom questionnaires were completed at enrolment, one week and month later, and monthly thereafter. Clinical severity was defined according to WHO criteria. Kaplan-Meier methods were used to compare time from illness onset to symptom recovery, by clinical severity. We examined determinants of time to recovery using multivariable Cox proportional hazards models. RESULTS: Between 11 May 2020 and 1 May 2021, 342 COVID-19 patients (192[56%] male) were enrolled, of whom 99/342(29%) had mild, 145/342(42%) moderate, 56/342(16%) severe and 42/342(12%) critical disease. The proportion of participants who reported at least one persistent symptom at 12 weeks after illness onset was greater in those with severe/critical disease (86.7%[95%CI=76.5-92.7%]) compared to those with mild or moderate disease (30.7%[95%CI=21.1-40.9%] and 63.8%[95%CI=54.8-71.5%]). At twelve months after illness onset, two-fifths of participants (40.7%[95%CI=34.2-47.1]) continued to report ≥1 symptom. Recovery was slower in female compared to male participants (aHR 0.65[95%CI=0.47-0.92]) and those with a BMI≥30kg/m 2 compared to BMI<25kg/m 2 (HR 0.62[95%CI=0.39-0.97]). CONCLUSIONS: COVID-19 symptoms persisted for one year after illness onset, even in some individuals with mild disease. Female sex and obesity were the most important determinants of speed of recovery from symptoms.

The clinical spectrum of coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranges from asymptomatic presentation to fatal illness.

Although the acute symptomatology of hospitalised patients has been well documented [1] [2] [3] [4] , robust longitudinal data on the evolution of long-term symptoms across the full range of COVID-19 severity is scarce. Moreover, little is known about the risk factors that may affect recovery and provide opportunity for intervention or treatment.

Observational studies have reported that more than half of hospitalised patients [5] [6] [7] and approximately one-third of non-hospitalised patients [8] reported at least one ongoing symptom four to twelve months after symptom onset. In addition, online patient-led support groups [9] have [5, 10, 11] .

The RECoVERED study is a prospective cohort study of individuals with SARS-CoV-2 infection residing in the municipal region of Amsterdam, the Netherlands. We evaluated the incidence, severity and duration of symptoms up to 12 months after illness onset in participants with mild, moderate, severe and critical COVID-19, and examined baseline determinants of time to recovery from symptoms.

A c c e p t e d M a n u s c r i p t

The RECoVERED study is an ongoing cohort study of individuals with COVID-19 in Amsterdam, the Netherlands. The study aims to describe the immunological, clinical and psychosocial sequelae of SARS-CoV-2 infection. Enrolment began on 11 May 2020. Non-hospitalised participants were identified from notification data of laboratory-confirmed (by polymerase chain reaction [PCR] or validated antigen test [12] ) SARS-CoV-2 infection at the Public Health Service of Amsterdam (PHSA).

Trained study staff approached eligible patients by telephone up to seven days after SARS-CoV-2 diagnosis. Prospectively-enrolled hospitalised participants were identified from admission data and approached on the COVID-19 wards of two academic hospitals in Amsterdam. In hospitals, COVID-19 diagnosis was based on positive PCR and/or SARS-CoV-2-specific serology (using the WANTAI SARS-CoV-2 Ab ELISA [13] ); the latter method was used as an additional diagnostic tool for cases with high clinical suspicion of COVID-19 during periods of extreme pressure on tertiary care. COVID-19 patients who had been admitted to ICU were enrolled following step-down from ICU. A limited number of hospitalised patients were contacted after discharge up to 30 June 2020 and within three months following SARS-CoV-2 diagnosis in order to include participants infected during the 'first wave' of COVID-19 in the Netherlands. Recruitment is ongoing; for the present analyses we included all participants with a follow-up of at least one month by 1 June 2021.

Eligibility criteria included prior laboratory confirmation of SARS-CoV-2 infection by PCR, validated antigen test or serology, as stated above. Further inclusion criteria were: aged 16-85 years, residing in the municipal region of Amsterdam, adequate understanding of Dutch or English. Individuals residing in a nursing home prior to SARS-CoV-2 infection were excluded due to inability to travel independently for follow-up appointments. Individuals with mental disorders that would interfere with adherence to study procedures were also excluded.

A c c e p t e d M a n u s c r i p t Figure S2 ). From month 2 after enrolment onwards, participants completed monthly online questionnaires on the presence of symptoms.

Heart rate (HR), respiratory rate (RR) and oxygen saturation (SpO 2 ) were measured at D0 and D7 study visits, or retrieved from hospital records for retrospectively-enrolled participants. Sociodemographic data and data on past medical history, COVID-19-related complications, treatment, and investigations were collected during participant interview. Self-reported data were verified with electronic medical records when available.

Definitions COVID-19 illness onset was defined as the first day of symptoms; for asymptomatic patients, date of SARS-CoV-2 diagnosis was used. Complete recovery was defined as resolution of all COVID-19 symptoms. As per National Institute for Health and Care Excellence (NICE) guidelines [15] , the acute phase of disease was defined as the first four weeks after illness onset, and post-COVID syndrome as symptoms persisting at least 12 weeks after illness onset.

Clinical severity groups were defined based on WHO COVID-19 disease severity criteria[16] using physical measurements from D0 and D7 study visits. Mild disease was defined as having a A c c e p t e d M a n u s c r i p t RR<20/min and SpO 2 >94% on room air at both D0 and D7 study visits; moderate disease as having a RR20-30/min and SpO 2 90-94% on room air (or receiving oxygen therapy, if no off-oxygen measurement available) at either visit; severe disease as having a RR>30/min and SpO 2 <90% on room air (or receiving oxygen therapy) at either visit; critical disease as requiring ICU admission as a result of COVID-19 at any point. Comorbidities at illness onset were those listed by the WHO as associated with severe COVID-19 [18] : cardiovascular disease (CVD), diabetes mellitus (DM), chronic lung disease (CLD), liver disease, chronic kidney disease, immunodeficiency, cancer, cerebrovascular disease, dementia or psychiatric illness. Obesity was excluded from the comorbidity variable because body mass index (BMI) was defined separately, categorised in kg/m 2 as: <25, underweight or normal weight; 25-30, overweight; >30, obese. Ethnicity was based on the country of birth of the study participant and their parents [19] .

Loss to follow-up (LTFU) was defined as active withdrawal from the study or two consecutive noshow appointments despite three attempts to establish contact. Date of LTFU was defined as the date of last contact with the participant.

Socio-demographic and clinical characteristics of participants were compared between clinical severity groups.

[CRF][14]) at one, four and twelve weeks after illness onset were calculated as the number of participants reporting each symptom since illness onset over the total number of participants in follow-up at that point, and was compared by clinical severity group. Asymptomatic participants A c c e p t e d M a n u s c r i p t contributed to the denominator. Given the potential recall bias in reporting symptom onset, we restricted this analysis to prospectively-enrolled participants. For symptoms reported by >20% of participants at 12 weeks after symptom onset, changes in self-reported symptom severity over time during the acute phase were visualised using transition plots, stratified by clinical severity group.

The proportion of participants with ongoing symptoms (overall and for each symptom separately) were estimated using Kaplan-Meier survival curves using data from both prospectively-and retrospectively-enrolled participants. The at-risk period began at illness onset and continued until symptom recovery, loss to follow up, 12 months after illness onset, date of first vaccination (to omit any effect of vaccination on time to recovery), or last study visit prior to 1 June 2021 (i.e. administrative censor date), whichever occurred first. Asymptomatic participants were excluded from all symptom survival analysis.

Analysis of determinants associated with time to recovery from symptoms is described in Supplementary Methods. Table 1) . All participants had prior confirmation of SARS-CoV-2 infection by PCR or antigen testing upon enrolment; none were enrolled solely on the basis of SARS-CoV-2-specific antibodies.

Participants with severe or critical disease were older than those with mild or moderate disease (p<0.001), had higher BMI (p<0.001) and more frequently had a diagnosis of CVD, CLD, or DM (Table   A c c e p t e d M a n u s c r i p t 1). Median time from illness onset to enrolment was 9 days (IQR=5-14) for prospectively enrolled and 85 days (IQR=72-94) for retrospectively enrolled participants. Until 1 June 2021, 66 participants were lost to follow-up. Two deaths, both due to COVID-19, occurred during follow-up.

Incidence proportions and severity of symptoms during the acute phase of infection Fatigue and cough were the most frequently reported symptoms overall and their incidence proportion during the acute phase did not differ between clinical severity groups (Supplementary Table S1 ). The incidence proportions of dyspnoea, headache and diarrhoea were significantly greater in those with severe/critical disease compared to those with mild or moderate disease during the acute phase of disease, whilst the opposite was true for loss of appetite, fever, rhinorrhoea and sore throat. Transition plots showed that although most participants transitioned to a lower level of severity over time for the more persistent symptoms (fatigue, dyspnoea, loss of smell and/or taste, and myalgia), some transitioned to a higher severity level over time (Supplementary Figures S3a-d) .

Time to complete recovery was significantly longer in symptomatic participants with moderate and severe/critical disease than in those with mild COVID-19 (Figure 1 ). At least one ongoing symptom was reported at 12 weeks after illness onset, thus meeting NICE criteria for post-COVID syndrome, by 30.7% (95%CI=21.1%-40.9%) of participants with mild, 63.8% (95%CI=54.8-71.5%) with moderate and 86.7% (95%CI=76.5-92.7%) with severe/critical disease. Among participants with mild disease, median time to complete recovery was 63 days (Figure 1 ), although 16.4%(95%CI=8.5-26.5%) continued to report at least one ongoing symptom at twelve months after illness onset. In those with moderate disease, median time to complete recovery was 232 days (7.6 months) and 49.5% (95%CI=39.6-58.6%) continued to report at least one symptom at 12 months after illness onset. 

Female participants experienced a 35% slower recovery than males (aHR 0.65 [95%CI=0.47-0.92]). In addition, obese participants recovered 38% more slowly than those of normal weight, when adjusting for age, sex and comorbidities (aHR 0.62 [95%CI=0.39-0.97]) ( Figure 2 ). The proportional hazards assumption was met for all covariates included in the model. When restricting the analysis to prospectively-enrolled participants, the effect of BMI was attenuated, suggesting that including retrospectively-enrolled participants, with more severe/critical disease and higher BMI, strongly influenced estimates of recovery time ( Figure S5 ).

In multivariable analysis of time to recovery for each of the four most persistent symptoms (Table   S2a -d), being obese at illness onset was associated with slower recovery from loss of smell and/or taste (aHR 0.51, 95%CI=0.32-0.82). Increased age was associated with slower recovery from dyspnoea (aHR 0.80, 95%CI=0.69-0.93) and myalgia (aHR 0.78, 95%CI=0.68-0.89). Number of comorbidities at illness onset was significantly associated with recovery from fatigue, where those with one comorbidity recovered twice as slowly as those without comorbidities (aHR 0.51, 95%CI=0.34-0.76). When we replaced total number of comorbidities with the presence of each of CVD, CLD, or DM in the multivariable models for each of these symptoms, no statistically significant effect on time to recovery was detected for any of these specific comorbidities.

A c c e p t e d M a n u s c r i p t

To our knowledge, this study is one of the first to report detailed longitudinal data on the evolution of COVID-19 symptoms in a cohort of individuals with mild to critical disease up to one year after illness onset. Despite an overall improvement in severity of the most persistent COVID-19 symptoms during the acute phase of disease, approximately one-third of the mild group, nearly two-thirds of the moderate group and more than four-fifths of patients with severe/critical disease met NICE criteria for post-COVID syndrome. Even at one year after illness onset, one in six of those with mild disease and approximately half of participants with moderate or severe/critical disease experienced at least one ongoing symptom. Female sex and obesity at illness onset were important determinants of slow recovery from symptoms.

Since the start of the COVID-19 pandemic, avoiding the immediate consequences of hospitalisation and mortality has been the primary goal of each public health strategy. Longer term sequelae of COVID-19 have received relatively little attention, especially among non-hospitalised patients. In our study, as many as one in three participants with mild COVID-19 still reported symptoms 12 weeks after illness onset. Indeed, the proportion of participants meeting the NICE definition of post-COVID syndrome in our cohort (60.2% overall) was comparable to other prospective cohort studies [7, 8, 20] , but higher than estimates by the UK Office for National Statistics and among healthcare workers [21, 22] . Although this could be partly explained by the fact that our analysis was limited to symptomatic participants, the consequences of these proportions when extrapolated to a global level are likely to be substantial. It is therefore clear that responding to this emerging public health crisis requires urgent attention.

A c c e p t e d M a n u s c r i p t Although patient advocacy groups have helped in making post-COVID syndrome a research priority[23], studies to date have differed in study population, follow-up time and symptoms evaluated [15] , making it difficult to synthesize all available evidence. Moreover, the symptom profiles that falls under post-COVID syndrome are diverse [24] , resulting in a heterogenous patient group requiring different management strategies. A universally accepted and evidence-based definition of post-COVID syndrome is key to comparing findings across studies and settings, and to develop syndrome-specific interventions. Our study, for example, shows recovery beyond approximately 6 months after illness onset is uncommon, suggesting that individuals who remain symptomatic beyond this point may require more intensive support and care. Moreover, our findings suggest that women and obese individuals, regardless of age and the number of comorbidities at illness onset, may benefit from early intervention. In addition to the direct effect of obesity on recovery, high BMI is associated with having a lower socio-economic status and reduced access to health and care services [25] , both of which may further amplify a slower recovery from symptoms. Reducing the prevalence of obesity may therefore help to reduce both acute complications [4, 26] and long-term sequelae of COVID-19.

Fatigue was the most commonly reported symptom both during the acute phase and at 12 weeks from illness onset, including among individuals with mild or moderate disease. Previous analyses have estimated that the societal impact of fatigue can be significant, due to both direct healthcare costs and indirect financial losses resulting from reduced economic productivity [27] . As those with mild COVID-19 represent the majority of COVID-19 cases worldwide in terms of absolute numbers, developing strategies to prevent, diagnose and manage post-COVID fatigue should be given priority.

Among participants with moderate and severe/critical disease, dyspnoea and myalgia additionally persisted beyond 12 weeks in a large proportion of participants. Similar results have been reported in other settings: previously-hospitalised COVID-19 patients in Wuhan, China still had abnormal A c c e p t e d M a n u s c r i p t chest imaging findings and pulmonary diffusing capacity at 6 months after illness onset [5] , whilst a cross-sectional study of hospitalised COVID-19 patients in the UK reported that the majority of participants reported myalgia at a median follow-up of 16 weeks after discharge from hospital [28] .

In our multivariable analysis, older age was the most important determinant of slower time to recovery from both of these symptoms. Exploring the underlying mechanism as to why these symptoms persist in older patients may help identify interventions that could be beneficial in the recovery process.

This study has several strengths. Frequent symptom questionnaires collected longitudinally since illness onset allowed the natural progression of COVID-19 symptoms to be described to a level of detail not previously reported. We were able to enrol patients with mild symptoms (underrepresented in other studies) as well as those who were critically ill, so that the full spectrum of COVID-19 disease could be represented. Several limitations must be recognised. Questionnaires in languages other than English and Dutch were not offered, therefore individuals with a migration background, who have been disproportionally affected by COVID-19, also in Amsterdam [29, 30] , were underrepresented in this cohort.

Furthermore, as the majority of our study participants were enrolled when wild-type SARS-CoV-2 was the dominant variant in the Netherlands, the progression of disease reported in our cohort may not be representative for patients infected with other SARS-CoV-2 variants [31] . In addition, certain symptoms that are frequently linked to post-COVID syndrome (e.g. 'brain fog', sleep disturbance) were not recorded. A further limitation was the effect of survival bias among retrospectively-enrolled participants (although sensitivity analysis of prospectively-enrolled participants rendered comparable results). In addition, those who were in a life-threatening situation when admitted to hospital were less likely to be A c c e p t e d M a n u s c r i p t S1]). Our study population might not be generalizable to those with extremely severe disease; however, these individuals have a high risk of death and symptom recovery is not applicable to deceased individuals. Finally, pre-COVID symptomatology was not recorded, making it difficult to accurately estimate the proportion of persistent symptoms directly attributable to post-COVID syndrome.

We demonstrated that post-COVID syndrome is common, even after mild disease. Symptoms M a n u s c r i p t 

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19

Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19)

Sequelae in Adults at 6 Months After COVID-19 Infection

COVID-19 and Sick Leave: An Analysis of the Ibermutua Cohort of Over 1,651,305 Spanish Workers in the First Trimester

Tracking the Economic Impact of COVID-19 and Mitigation Policies in Europe and the United States

RIVM. Status validatie SARS-CoV-2 antigeensneltesten In: Infectieziektebestrijding C. 19

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Council MR. MRC Dyspnoea scale / MRC Breathlessness scale

Clinical management of COVID-19: WHO Headquarters (HQ)

The utility of 'country of birth' for the classification of ethnic groups in health research: the Dutch experience

Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol

Update on long COVID prevalence estimate

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA 2021. 23. Nature. Long COVID: let patients help define long-lasting COVID symptoms

Socioeconomic Status and Obesity

Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death -United States

The hidden cost of chronic fatigue to patients and their families

Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?

Hospitalisation rates differed by city district and ethnicity during the first wave of COVID-19 in Amsterdam, the Netherlands

SARS-CoV-2 antibody prevalence and determinants of six ethnic groups living in Amsterdam, the Netherlands: a populationbased cross-sectional study

Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages. The Lancet Public Health

The authors wish to thank all RECoVERED study participants. Additionally we to thank Daniëla van Santen for helping to create the transition plots.RECoVERED Study Group:

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Days from illness onset to: A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t